Navigation Links
Phase 3 trials of two multi-kinase inhibitors against cancer

Sorafenib and stutent multi-kinase inhibitors against cancer is undergoing phase 3 trials// and these two drugs gained more appreciation in this years ASCO (American Society of Clinical Oncology) conference. This drug is gaining interest due to its multiple mechanism of action – known as Multi-kinase inhibitors. These drugs are in trial against different types of cancer and are found to be very effective. This two multi targeted oncology drug candidate is a small molecule named Sorafenib (Bay43-9006) and stutent (SU11248).

Sorafenib is produced by Onyx pharmaceuticals of California collaborating with Bayer pharmaceuticals of Connecticut and Stutent by Pfizer of New York city. Both these drugs are undergoing phase 3 trials.

Results of the study show that Sorafenib in advanced kidney cancer patients taking the drug lived twice as long as that placebo. Gleevec (imatinib) resistant gastrointestinal stromal tumors (GIST) were much less likely to progress in patients taking stutent versus those on placebo.

Both these drug act against tumor and its ability to recruit new blood vessels essential for growth and dissemination via multiple mechanisms. Sorafenib works by inhibiting the RAF/MEK/ERK pathway and, in parallel, impedes angiogenesis by inhibiting vascular endothelial growth factor-2 (VEGF-2) and platelet derived growth factor beta (PDGF- a). Stutent also has dual actions, killing VEGF and PDGF- á and a as well as FLT-3 and C-KIT.

Pfizer is developing more multi-targeted cancer drugs, such as small AG-013736 which has encouraging results in its phase 2 trials in kidney cancer.

Multi-targeted drug has also downsides of having side effects and allow less flexibility. But, so far there was no side effects reported in Sorafenib or stutent.


'"/>




Page: 1

Related medicine news :

1. SARS-Free Taiwan to Mark End Phase of Global Fight
2. Spray on contraceptive clears Phase I trial
3. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
4. Phase II trails of new HIV vaccine to be held in South Africa
5. FDA approves Phase 0 trial which tests experimental drugs on humans
6. Jalgaon: Third Phase Of Culling Operations Begin
7. Phase 1 Drug Trials on Humans to Be Made Public
8. Lupin Gets DCGI Nod For Phase II Clinical Trials On Desoside-P
9. Cadila to Commence Phase I Clinical Trials On ZYH2
10. iGATE Completes Phase I Testing Of Meningitis Vaccine
11. ADHD Treatment -Phase 3 data on Lisdexamfetamine dimesylate Presented
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/23/2017)... (PRWEB) , ... August 23, 2017 , ... This week ... claims firms in Texas. Founded by Bill Voss, the firm grew quickly and has ... and a half of helping clients get the money they deserve from their insurance ...
(Date:8/23/2017)... (PRWEB) , ... August 23, 2017 , ... Earlier this ... authority on the use of health IT to create efficiencies in healthcare information exchange ... held its 2017 Summer Forum which featured keynote addresses by Donald W. ...
(Date:8/23/2017)... ... August 23, 2017 , ... The Stevie® Awards have announced the winners of the Best ... world’s premier business awards competition. , Nominees in the 2017 IBAs were not able to ... system based on the total number of awards won in the IBAs with a Gold ...
(Date:8/23/2017)... ... August 23, 2017 , ... Cirrus Medical Staffing, ... new website, http://www.cirrusmedicalstaffing.com . The new site pairs a robust job search ... professionals who are traveling on short-term assignments to healthcare facilities around the country. ...
(Date:8/23/2017)... ... 2017 , ... MobilityWorks ®, the nation's largest retailer ... Inc. 500|5000, an exclusive ranking of America’s fastest-growing private companies. MobilityWorks (aka WMK) ... the twelfth year that the company has been included on the list. , ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... Inc. announced today that its fully owned USA ... York City Office in Yonkers, New York ... (TWO 2 ) homecare therapy. This new East Coast location has ... under the company,s DMEPOS accreditation for Home/Durable Medical Equipment Services. ... Advanced Oxygen Therapy Inc. New ...
(Date:8/11/2017)... 11, 2017 DarioHealth Corp. (NASDAQ: DRIO), a ... big data solutions, today announced that it will release ... and host a conference call at 9:00am ET. The ... financial results and its strategy and outlook for the ... Erez Raphael , Chief Executive Officer, and ...
(Date:8/8/2017)... Aug. 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a ... reports its financial results for the second quarter ended ... the second quarter 2017 and to date: ... development programs for the Company,s lead project, BL-8040: ... study with BL-8040 as novel stem cell mobilization treatment ...
Breaking Medicine Technology: